A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

ClinicalTrials.gov ID: NCT03987763

Public ClinicalTrials.gov record NCT03987763. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.

Study identification

NCT ID: NCT03987763
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: Bausch Health Americas, Inc.; Industry
Enrollment: 45 participants

Conditions and interventions

Conditions

Psoriasis

Interventions

IDP-122 Lotion Drug

Drug

Eligibility (public fields only)

Age range: 6 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 21, 2019
Primary completion: Apr 30, 2026
Completion: May 31, 2026
Last update posted: Aug 26, 2025

2019 – 2026

United States locations

U.S. sites: 7
U.S. states: 4
U.S. cities: 6

Facility	City	State	ZIP	Site status
Bausch Site 11	Fountain Valley	California	92708	Terminated
Bausch Site 2	Thousand Oaks	California	91320	Recruiting
Bausch Site 07	Doral	Florida	33166	Recruiting
Bausch Site 3	Miami	Florida	33125	Recruiting
Bausch Site 06	Miami	Florida	33155	Terminated
Bausch Site 05	Spartanburg	South Carolina	29303	Terminated
Bausch Site 1	Spokane	Washington	99216	Terminated

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03987763, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 26, 2025 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03987763 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →